Association of anticoagulant choice with death in the primary treatment of noncancer venous thromboembolism: Medicare 2011-2018.

ABSTRACT: Direct oral anticoagulants (DOACs; namely, rivaroxaban and apixaban) and warfarin are approved for venous thromboembolism (VTE) treatment. Few direct comparisons exist of DOACs on risk of death among patients with VTE, and for patients with concomitant conditions (eg, kidney disease, liver disease), clinical guidelines are unclear. We evaluated 6-month all-cause mortality by anticoagulant prescribed for primary treatment of VTE. Using data from a 20% sample of Medicare beneficiaries, we created a propensity score-matched analytic data set of 47 860 beneficiaries with noncancer incident VTE. We used Cox regression to estimate adjusted hazard ratios (HRs) of OACs with 6-month mortality, and tested interactions by liver and kidney disease. There were 3422 deaths over 6 months of follow-up. In

SUBMITTER: Walker RF 

PROVIDER: S-EPMC12210015 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature